Autoimmune hemolytic anemia in chronic lymphocytic leukemia View PDF

^*Amelia Maria Gaman
Medicine, University Of Medicine And Pharmacy Of Craiova, Craiova, Romania

^*Corresponding Author:

Amelia Maria Gaman
Medicine, University Of Medicine And Pharmacy Of Craiova, Craiova, Romania
Email:gamanamelia@yahoo.com

Published on: 2014-03-21

Abstract

Chronic lymphocytic leukemia (CLL) is a malignant proliferation of mature, differentiated B-lymphocytes, frequently associated with autoimmune hemolytic anemia (AIHA). The effect of this complication in the clinical outcome and survival of patients with CLL is controversial. The aim of study was to evaluate the prevalence of AIHA in our patients with CLL and how this complication influences the patient's survival.

Keywords

CLL; AIHA; Survival

Introduction

Chronic lymphocytic leukemia (CLL) is a malignant proliferation of mature, differentiated lymphocytes, mostly of B-cell origin, frequently associated with autoimmune cytopenia (autoimmune hemolytic anemia and immune thrombocytopenia). Autoimmune hemolytic anemia (AIHA), defined as an acquired hemolytic anemia in which the destruction of erythrocytes is mediated by anti-erythrocyte auto antibodies, occurs in 5-38% of patients with CLL.